MTaI seeks level playing field for global medical device industry in India
MTaI urges balanced regulation to ensure quality healthcare, warning harsh price caps, GST, and misuse of devices could harm patients and innovation.
Read More
10% price hike cap on most medical devices
NPPA allows up to 10% annual price hikes for most medical devices, caps stents, and warns of strict action against overcharging.
Read More
Cut in stent prices to hit biz environment, says association
Sharp stent price cuts could hurt markets and R&D, prompting calls for broader regulation, GST relief for healthcare, and checks on reuse of single-use devices.
Read More
Budget 2017: Gold for medical device sector, and a cold breeze to healthcare industry
Budget boosts medical devices and education, but falls short of pharma growth goals; industry welcomes device rules and global harmonisation push.
Read More
A Cautious Approach To GST Would Catapult India To High-Ranking Economies Of The World
Medtech leaders urge GST to keep healthcare and devices low-taxed, warning higher duties and rates could raise costs and hurt access.
Read More
Makers, hospitals conspire to fleece stent recipients
After NPPA stent price caps, fears of shortages surface as hospitals and firms are accused of withdrawing brands or shifting costs to procedures.
Read More
Medical device industry is disappointed with some of the points in the draft gazette notification of Medical Device rules
PavanChoudary, Director General, MTaI says, “We are disappointed that some points on which the Health Ministry had agreed to are not reflected in the draft rules. We are optimistic that continuing in the inclusive & consultative tone set by the ministry
Read More
Govt’s latest set of medical devices rules fail to impress industry
Medical device makers, Indian and MNCs alike, oppose new device rules, citing short licence terms, compliance burden, and risks to Make in India.
Read More
Medical devices regulation 2.0 draws industry's ire
Stricter import rules on device shelf life draw industry pushback, with firms calling draft rules restrictive, misaligned with global norms.
Read More